Lymphoma: all 5,624 studies
Page 25 of 57. Open to participants first (824), then studies with results posted, then the rest; newest registration first within each.
- A Study of Chinese Adults With LymphomaCompletedNCT05288491
- A Phase II Trial of Intermediate Radiation Dose For LymphomaStatus unknownNCT05284825Not applicable
- A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell LymphomaStatus unknownNCT05274997Phase 2
- Treatment of Primary CNS Lymphoma ( FTD )CompletedNCT05274139Phase 2
- A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLLTerminatedNCT05272813Phase 1/2
- A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological MalignanciesCompletedNCT05269940Phase 1/2
- Safety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCLStatus unknownNCT05269914Not applicable
- A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHLTerminatedNCT05265975Phase 1/2
- Sepantronium Bromide for the Treatment of High-grade B-cell LymphomaActive, not recruitingNCT05263583Phase 2
- MargheRITA (Remote Intelligence for Therapeutic Adherence)CompletedNCT05260203Not applicable
- Feasibility, Acceptability, and Preliminary Effects of LymfitCompletedNCT05259657Not applicable
- PET Guided Bone Marrow Biopsy vs Trephine Bone Marrow BiopsyCompletedNCT05251168
- A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT05244070Phase 1
- GB5121 in Adult Patients With Relapsed/Refractory CNS LymphomaTerminatedNCT05242146Phase 1
- Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCLWithdrawnNCT05239910Phase 2
- Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant LymphomaStatus unknownNCT05239676Early Phase 1
- Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma (ATL) and Patients Chronically Infected With the HTLV-1 Virus (HTLV-OBS)Active, not recruitingNCT05237245
- Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHLCompletedNCT05233033Phase 1
- Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT05228249Phase 1
- Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid TumorsCompletedNCT05225584Phase 1
- Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post TransplantWithdrawnNCT05222438Phase 2
- Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin LymphomaTerminatedNCT05221385Phase 1
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaTerminatedNCT05219513Phase 1
- A Study to Learn More About Copanlisib Treatment Patterns in People With Indolent Non-Hodgkin Lymphoma, a Type of Cancer That Grows and Spread Slowly and Develops in the Lymphatic System (a Part of Immune System) in Taiwan Under Real-word ConditionsCompletedNCT05217914
- Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LLNo longer availableNCT05215405
- Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell LymphomaActive, not recruitingNCT05214183Phase 2
- An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory LymphomaStatus unknownNCT05208853Early Phase 1
- Clinical Study of SL19+22 CAR-T Cells for Relapsed or Refractory Non-Hodgkin LymphomaStatus unknownNCT05206071Not applicable
- Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell LymphomaActive, not recruitingNCT05202782Phase 2
- A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell LymphomaStatus unknownNCT05200312Phase 2
- Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With TisagenlecleucelTerminatedNCT05199961Not applicable
- Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid StudyStatus unknownNCT05191225Phase 4
- Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant LymphomaCompletedNCT05190263
- HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT05190068Phase 1
- Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell LymphomaStatus unknownNCT05189782
- Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory LymphomaCompletedNCT05189093Phase 1/2
- Fitness Assessment in Young Adults Recovered From LymphomaCompletedNCT05188755Not applicable
- FDG PET/CT and Directed Metabolic Core Needle Biopsy in the Management of LymphomaCompletedNCT05186610
- A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell TransplantationTerminatedNCT05181540Phase 3
- Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell LymphomaStatus unknownNCT05179213Phase 2
- HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHLWithdrawnNCT05176691Phase 1
- PET / CT Imaging and Safety in Patients With Lymphoma Treated With CD19 Car-t CellsStatus unknownNCT05176275Not applicable
- Clinical Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Recurrent/Refractory Lymphoma SubjectsCompletedNCT05173545Phase 1
- Expanded Access Program for Pirtobrutinib for Participants With B-Cell CancerApproved for marketingNCT05172700
- A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)TerminatedNCT05169489Phase 1
- Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors at Risk for Cardiovascular Morbidity and Frailty, The MOBILE AYA StudyWithdrawnNCT05169151
- Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin LymphomaStatus unknownNCT05164770Phase 3
- Long-term Registry of Patients Treated With Loncastuximab TesirineWithdrawnNCT05160064
- PEG-rhG-CSF Compared With rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell TransplantationStatus unknownNCT05156554Not applicable
- A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL).TerminatedNCT05156229Phase 1
- Safety and Preliminary Efficacy Study of MRG001 in Patients With Non-Hodgkin Lymphoma (NHL)Status unknownNCT05155839Phase 1
- Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell LymphomaStatus unknownNCT05155215Phase 1/2
- Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLLTerminatedNCT05153330Phase 1
- Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular LymphomaWithdrawnNCT05152459Phase 1/2
- Muscle Dysfunction in Patients With Haematological DiseasesActive, not recruitingNCT05150561
- Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCLStatus unknownNCT05149170Phase 2
- Study of XL114 in Subjects With Non-Hodgkin's LymphomaTerminatedNCT05144347Phase 1
- Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell LymphomaStatus unknownNCT05143112Phase 1/2
- A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCLSuspendedNCT05138458Phase 1/2
- PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's LymphomaStatus unknownNCT05137886Phase 2
- A Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)CompletedNCT05137847
- (TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).WithdrawnNCT05134740Phase 1
- Characterisation of TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System Diffuse Large B Cell LymphomasCompletedNCT05133505
- The BurnAlong Pilot Study for Adolescent and Young Adult Cancer SurvivorsCompletedNCT05131815Not applicable
- An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)No longer availableNCT05131438
- CAR T Cell Therapy Related Cardiovascular OutcomesCompletedNCT05130489
- A Complex Intervention for Chronically Fatigued Lymphoma SurvivorsActive, not recruitingNCT05130099Not applicable
- A Phase I Study of ZN-d5 in Chinese Subjects With Non-Hodgkin LymphomaTerminatedNCT05127811Phase 1
- Safety and Efficacy of ThisCART7 in Patients With Refractory or Relapsed T Cell MalignanciesStatus unknownNCT05127135Phase 1
- A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or LymphomaActive, not recruitingNCT05115292Phase 1
- Combining Intratumoral Metabolic Heterogeneity and Dissemination Feature (Dmax) on 18F-FDG PET/CT Improves Prognosis Prediction in DLBCLCompletedNCT05113576
- PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell MalignanciesTerminatedNCT05107856Phase 1
- Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.WithdrawnNCT05106192Not applicable
- Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell LymphomasTerminatedNCT05105412Phase 1/2
- Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin LymphomaStatus unknownNCT05097443Phase 3
- 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in LymphomaTerminatedNCT05096234Phase 1
- Study of the Prognostic Role of Gene Polymorphism in the Development of B-cell Leukemias and Lymphomas in Children of Kazakh NationalityCompletedNCT05095155
- Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCLStatus unknownNCT05093140Phase 2
- Prospective Comparison of 18F-FDG and 18F-FET PET for Response Evaluation in Patients With Primary Central Nervous System LymphomaStatus unknownNCT05083936Not applicable
- A Study of N-Acetylcysteine (N-AC) in People Receiving CAR T-cell Therapy for LymphomaActive, not recruitingNCT05081479Phase 1
- UPLYFT For Lymphoma SurvivorsCompletedNCT05080166Not applicable
- A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or LymphomaCompletedNCT05078593Phase 1
- A Study of OLR in First-line Treatment of Mantle Cell LymphomaStatus unknownNCT05076097Phase 2
- Endobronchial Diagnosis of LymphomaStatus unknownNCT05075655Not applicable
- Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T TherapyCompletedNCT05064787Not applicable
- CD7 CAR T-cell for R/R CD7+ T Cell LymphomaStatus unknownNCT05059912Phase 2
- Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell LymphomaCompletedNCT05058755Not applicable
- Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT StudyCompletedNCT05053100
- Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBLStatus unknownNCT05050630Phase 2
- Nutrition and Physical Activity Intervention in Preventing Excess Weight Gain in Pediatric Patients With Leukemia or Lymphoma Treated With Prednisone and/or DexamethasoneCompletedNCT05049785Early Phase 1
- Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.Status unknownNCT05049473Phase 2
- Imaging Apoptosis for Lymphoma Treatment ResponseTerminatedNCT05048732Early Phase 1
- XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic LeukemiaTerminatedNCT05038644Phase 1
- Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and LymphomaWithdrawnNCT05037669Phase 1
- Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS LymphomaStatus unknownNCT05021770Phase 1/2
- Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin LymphomaActive, not recruitingNCT05019976Not applicable
- Breast-implant ASsocIated anaplastIc Large Cell Lymphoma and CApsular ContractureStatus unknownNCT05017337
- Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell LymphomaStatus unknownNCT05014100Phase 2
- CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's LymphomaStatus unknownNCT05013372Early Phase 1
- DOLPHIN-VIVO: Diagnosis Of LymPHoma IN Vivo (In Vivo Phase)TerminatedNCT05010369Not applicable